Navigation Links
Aragon Pharmaceuticals Announces $8 Million Series A Financing
Date:5/20/2009

LA JOLLA, Calif., May 20 /PRNewswire/ -- Aragon Pharmaceuticals today announced it has raised $8 million in Series A financing led by The Column Group and OrbiMed Advisors. Funds from the Series A financing will be used to discover and develop new small molecule therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.

Aragon Pharmaceuticals is a San Diego-based biopharmaceutical company built on the pioneering research of Charles Sawyers, M.D., an investigator at Memorial Sloan Kettering Cancer Center and the Howard Hughes Medical Institute, and Michael Jung, Ph.D., a professor at UCLA, who are founders of Aragon. Their recent discoveries show that the biology of hormone-resistant cancers can be overcome through the creation of a new class of nuclear receptor targeting drugs, thereby opening the door to a pipeline of new anti-endocrine therapies. This approach will produce drugs that are mechanistically distinct from existing therapies in the clinic and the current research pipeline.

Aragon is bringing together a proven team to drive the drug discovery programs. The Company is led by Richard A. Heyman, Ph.D., President and Head of Research and Development, who has worked in the nuclear receptor drug discovery field for 20 years and brought multiple compounds into the clinic and market. Aragon's Board of Directors includes Richard Heyman, Peter Svennilson, Founder and Managing Partner of The Column Group and Carl Gordon, founding General Partner of OrbiMed.

Rick Klausner, Aragon's Co-Chairman of the Scientific Advisory Board, Managing Partner at The Column Group, and former Director of the National Cancer Institute, stated that "30% of all cancers arise from hormone responsive tissues and hormonal therapy has been one of the bedrocks of cancer treatment. Unfortunately most of these tumors are or become resistant to available therapies. Breakthrough science has created the opportunity for Aragon to solve the problem of treatment resistance by creating a new approach to hormone receptor therapy."

"Aragon will build off the work of our founders and focus on the discovery and development of compounds that target the degradation of the androgen and estrogen receptor, to treat patients with hormone refractory disease," stated Dr. Richard Heyman. "The company has recruited an experienced drug discovery team and several world-renowned scientists to the Scientific Advisory Board to help guide the discovery and development of our research programs."

Peter Svennilson noted, "It is the caliber of the people behind Aragon and the tremendous potential that this approach has for treating hormone dependent cancers that excited us about funding this opportunity. The Aragon team is poised to generate a pipeline of novel cancer therapies and I look forward to working with Aragon to achieve their vision to effectively treat hormone refractory cancers."

For more information, please see:

http://www.aragonpharmaceuticals.com

or email:

info@aragonpharmaceuticals.com


'/>"/>
SOURCE Aragon Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Paragon Technologies SI Systems Brand Awarded A $1.0 Million System Expansion Contract for an Automated Light-Picking System
2. Paragon Medsystems Becomes California MedTech
3. Paragon Benefits, Inc. Selects North Star Health for Data Analysis and Cost Management Reporting
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Jacksonville, Fla. (PRWEB) , ... February 22, 2017 ... ... aneurysms is just as effective on smaller and sometimes harder to reach ones, ... findings were presented at the International Stroke Conference in Houston by Ricardo A. ...
(Date:2/22/2017)... , ... February 22, 2017 ... ... of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp ... which provides instant absorption from the mouth into the bloodstream. Far ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery management ... on the App Store and Google Play . Florida-based Sober Network, ... and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management app ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, ... latest innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are ... management, to accelerate tissue synthesis and provide a faster and more efficient healing ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five ... of those report that family members or friends have also commented about their ... hearing loss wear hearing aids. One reason, suggested by 89 percent of American ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... India , February 22, 2017 According ... Product (Scissors, Forceps, Trocar, SIMS, CUSCO), Application (Laparoscopy, Colposcopy, Hysteroscopy, D&C, ... Global Forecast to 2021", published by MarketsandMarkets, the global market is ... Billion in 2016, at a CAGR of 7.1% during the forecast ... ...
(Date:2/22/2017)... DUBLIN , Feb 22, 2017 ... "Dermatology Therapeutics Drug Development Pipeline Review, 2016" report to ... ... types of disorders worldwide, and approximately one-third of the US ... the past decades, the majority of the dermatology market has ...
(Date:2/22/2017)... A research report by Arcview Market Research ... and the continuously changing landscape of the legal market reveals that ... North America , a 30% increase from 2015. According ... by the year 2021 representing a 26 percent compound annual growth ... and Canada is gradually becoming ...
Breaking Medicine Technology: